AccuStem Sciences, Inc. (ACUT)
| Market Cap | 2.57M -91.5% |
| Revenue (ttm) | 98.40K |
| Net Income | -1.65M |
| EPS | -0.10 |
| Shares Out | 16.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,517 |
| Open | 0.2300 |
| Previous Close | n/a |
| Day's Range | 0.1600 - 0.2300 |
| 52-Week Range | 0.1515 - 2.2500 |
| Beta | 1.91 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About AccuStem Sciences
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York,... [Read more]
Financial Performance
Financial StatementsNews
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today ann...
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
PHOENIX, Ariz. and LONDON, Sept.
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced th...
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk o...
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cance...
AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cance...
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT...
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and Emeritus...
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs furthe...
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.
BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re...
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today...
AccuStem Announce Strategic Clinical and Operational Partnership
LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announc...
AccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast Cancer
LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced tod...
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced to...
AccuStem Announces Adjournment of Annual Meeting of Stockholders
LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced tod...
AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast Cancer
LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, anno...
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce i...
AccuStem Announces Private Placement of Common Stock
LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it has...
AccuStem Sciences, Inc. Appoints New Executive Leadership Team
Company plans to uplist to the Nasdaq Capital Market Company plans to uplist to the Nasdaq Capital Market